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Abstract 
A number of tools based on high-performance affinity separations have been developed 
for studying drug-protein interactions.  An example of one recent approach is ultrafast affinity 
extraction.  This method has been employed to examine the free (or non-bound) fractions of 
drugs and other solutes in simple or complex samples that contain soluble binding agents.  These 
free fractions have also been used to determine the binding constants and rate constants for the 
interactions of drugs with these soluble agents.  This report describes the general principles of 
ultrafast affinity extraction and the experimental conditions under which it can be used to 
characterize such interactions.  This method will be illustrated by utilizing data that have been 
obtained when using this approach to measure the binding and dissociation of various drugs with 
the serum transport proteins human serum albumin and alpha1-acid glycoprotein.  A number of 
practical factors will be discussed that should be considered in the design and optimization of 
this approach for use with single-column or multi-column systems.  Techniques will also be 
described for analyzing the resulting data for the determination of free fractions, rate constants 
and binding constants.  In addition, the extension of this method to complex samples, such as 
clinical specimens, will be considered.   
 
 
Keywords: ultrafast affinity extraction; human serum albumin; alpha1-acid glycoprotein; drug-
protein interactions; affinity microcolumn; high performance affinity chromatography 
 
Abbreviations: AGP, alpha1-acid glycoprotein; HPAC, high performance affinity 
chromatography; HPLC, high performance liquid chromatography; HSA, human serum albumin 
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1. Introduction 
The extent of binding by many drugs to serum proteins can play a significant role in 
determining the eventual activity and fate of these drugs in the circulation [1,2].  This makes the 
measurement of a drug’s ability to bind to these proteins an important item to consider during the 
discovery, development and use of a new pharmaceutical [2].  The binding of a drug with agents 
in blood is often reversible and results in both bound and free fractions for the drug.  Because the 
bound form of a drug cannot usually cross a cell membrane or bind to a receptor, it is the free 
fraction that often determines the overall activity of the drug [1-4].  Two serum proteins that bind 
to a broad range of drugs are human serum albumin (HSA) and alpha1-acid glycoprotein (AGP, 
or orosomucoid) [2].  More complex agents such as lipoproteins can also be involved in binding 
to drugs in the circulation [5-11].   
A number of techniques have been utilized to study and measure the binding of drugs 
with serum proteins and other biological agents [2,7,12-33].  These methods have included 
separation-based approaches such as equilibrium dialysis, ultrafiltration, liquid chromatography 
and capillary electrophoresis.  A number of spectroscopic methods have also been employed for 
this work, such as absorbance, fluorescence, circular dichroism, nuclear magnetic resonance, and 
surface plasmon resonance spectroscopy.  Differential scanning calorimetry and isothermal 
titration calorimetry have been used as well for this purpose [2,7,12-33]. 
Another method that has been explored for studying drug-protein binding is high 
performance affinity chromatography (HPAC) [1,3,34-40].  In HPAC, a biological binding agent 
is used as a stationary phase for the isolation or analysis of components in a sample [1].  The 
retention of injected or applied solutes in HPAC is based on the specific and reversible 
interactions that occur in biological systems (e.g., drug-protein binding).  This type of binding is 
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combined in HPAC with supports such as silica particles or monolithic materials that have good 
mass transfer properties and are capable of withstanding the pressures and flow rates that are 
present in systems for high performance liquid chromatography [41]. 
HPAC has been used in a variety of formats to determine binding constants for drug-
protein interactions, to study drug-solute competition for proteins, to characterize the binding 
sites for these processes, and to describe the rates of these interactions [1,42].  Some advantages 
of using HPAC for this type of work are its speed, precision, ability to be automated, and need 
for only a small amount of a protein or binding agent.  Other attractive features of HPAC are its 
compatibility with many types of detectors, its good correlation with solution-based methods, 
and its ability to often reuse the same immobilized binding agent for many samples [1,3,12,42].   
Ultrafast affinity extraction is an HPAC technique that has been recently developed for 
studying drug-protein binding [43-54].  Figure 1 illustrates the basis of this technique.  This 
method uses an affinity microcolumn to extract the free fraction of a drug from a sample on a 
time scale that minimizes or allows controlled dissociation of the drug from its soluble binding 
agents.  This approach has been used to measure the free fractions of drugs and other solutes in 
solute/protein mixtures and in biological samples [43-54].  The same method has also been used 
to determine equilibrium constants and rate constants for drug-protein interactions [49,54].   
This report will describe the general principles of ultrafast affinity extraction and various 
factors to consider when using this method to characterize drug- or solute-protein interactions.  
Practical aspects that will be considered will include the types of formats that can be used in this 
method; factors to optimize when using this method for free fraction measurements; and 
techniques for analyzing the resulting data to obtain equilibrium constants or rate constants.  
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These items will be illustrated by using data that have been previously acquired by this method 
for various drugs that are known to bind to HSA or AGP in serum or blood [44-46,52,53]. 
 
2. Materials 
The chemicals and biochemicals that are used in ultrafast affinity extraction should have 
known purities and be obtained from sources that have good batch-to-batch reproducibilities for 
these reagents.  All buffers and aqueous solutions that are used in this method should be prepared 
using deionized water, as obtained from water purification devices such as a Milli-Q Advantage 
A10 system (Millipore, Billerica, MA, USA) or a NANOpure system (Barnstead, Dubuque, IA, 
USA).  The aqueous buffers and solutions employed in ultrafast affinity extraction should ideally 
be filtered prior to injection or application to an HPLC system, such as by using 0.22 µm GNWP 
nylon filters from Fisher Scientific (Pittsburgh, PA,USA) or comparable filtration devices. 
   
2.1. Solution and mobile phase preparation 
The mobile phase used for ultrafast affinity extraction should mimic the pH and solution 
composition of the biological system that is being examined [1].  For the study of drug 
interactions with serum proteins, one common mobile phase that is used is 0.067 M potassium 
phosphate buffer, pH 7.4 [42].  This buffer can be prepared by dissolving 7.546 g of monobasic 
potassium phosphate and 37.724 g of dibasic potassium phosphate in 4.00 L water.  The pH of 
this solution can then be adjusted to 7.40 by the slow addition of low concentrations of either 
hydrochloric acid or sodium hydroxide.  After this buffer has been prepared and filtered, it 
should be stored at 4ºC when not in use.  Other buffers or solutions can also be used as the 
mobile phase in ultrafast affinity extraction, depending on the nature of the system and types of 
interactions that are to be characterized. 
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The drug solutions to be used as standards or to be mixed with proteins should be ideally 
prepared in the mobile phase and combined with a known amount of the protein or added to a 
protein solution with a known concentration and that is prepared in the mobile phase.  For 
example, in work with propranolol, a stock solution of 100 μΜ propranolol can be prepared by 
dissolving 2.95 mg of propranolol in 100 mL of a 0.067 M phosphate buffer, pH 7.4, and stirring 
the solution overnight.  This stock solution can be diluted with 0.067 M phosphate buffer, pH 
7.4, to prepare a 1 μΜ standard solution.  In examining the binding of this drug to AGP, a 4.1 mg 
portion of AGP can be dissolved in 5 mL of the 1 µM propranolol working solution to give a 
sample that contains 1 µM propranolol and 20 µM AGP.  Other drug and protein combinations 
can be used to make samples with alternative concentrations.  Biological samples such as serum 
that have a known volume can be spiked directly with a small volume of a solution that contains 
a known concentration of the drug to be studied [52,53]. 
A sample/protein mixture that is used in ultrafast affinity extraction should be incubated 
at the desired temperature for interaction studies (e.g., 37ºC for work under physiological 
conditions) at least a half hour before it is used in any binding experiments.  The individual drug 
and protein solutions or remaining drug/mixture should be stored, when not in use, under 
appropriate conditions to provide good stability for these reagents.  For serum proteins, this often 
involves storage of these solutions at 37ºC.  However, the length of time over which such 
solutions can be stored should be determined for each new drug or protein to ensure good 
stability for these reagents is present over the course of the binding studies. 
2.2.  Preparation of affinity microcolumns 
Immobilized HSA or AGP was used as the stationary phase for the affinity microcolumns 
in the examples provided in this report because of the ability of these serum proteins to undergo 
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fast and reversible binding to a wide range of drugs, as well as their ability to later elute these 
drugs under isocratic conditions at a physiological pH [1,48,50,55].  The affinity microcolumns 
and columns that were used in these prior reports had a typical inner diameter of 2.1 mm and 
lengths of 0.1-5.0 cm. However, other column dimensions can also be employed for ultrafast 
affinity extraction as long as the total column residence times are suitable for isolation of a free 
drug fraction.  It was found for many drugs that the desired residence times are usually in the 
range of approximately 0.1-0.9 s when using HSA or AGP as the soluble binding agent 
[45,47,49,53,54].   
A variety of supports can be used for HSA or AGP immobilization.  The specific 
examples that were utilized in this report used Nucleosil Si-300-7 porous silica (7 μm particle 
size, 300 Å pore size) from Macherey-Nagel (Duren, Germany).  However, other types of porous 
silica or even monolithic supports can also be modified for use in this type of work [56-58].    
Many methods can be used to immobilize HSA onto porous silica or other types of HPLC 
supports [47,56-58,59-62].  One common example of such a technique is the Schiff base method, 
which is illustrated in Figure 2(a).  In this method, a support such as silica is first converted into 
or obtained in a diol-bonded form [58,59,60].  This form enables the support to have low non-
specific binding for many drugs and biological agents and makes this support easy to further 
modify for the immobilization of proteins or other binding agents [59,60,63].  The diol groups 
are then oxidized to aldehyde groups, which can be combined with primary amines on a protein 
such as HSA to form a Schiff base.  The Schiff base is then converted to a secondary amine upon 
its formation by using sodium cyanoborohydride as a reducing agent.  After immobilization has 
taken place, sodium borohydride is often added to reduce any remaining aldehydes to form 
alcohol groups [56,59,60]. 
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The following conditions can be used to immobilize HSA to Nucleosil Si-300-7 silica by 
the Schiff base method.  To make 0.10 g of HSA silica, 0.10 g of diol silica is first oxidized to 
form aldehyde groups by placing this support into 2 mL of 90% acetic acid that contains 0.10 g 
periodic acid.  This mixture is covered with aluminum foil and shaken for 2 h at room 
temperature.  The aldehyde-activated silica is then washed several times with water, followed by 
washing with 0.10 M potassium phosphate buffer, pH 6.0.  The aldehyde-activated silica is next 
suspended in 0.5-1.0 mL of the 0.10 M phosphate buffer, pH 6.0, and combined with 10 mg 
HSA and 23 mg sodium cyanoborohydride.  This mixture is allowed to react, with gentle 
shaking, for at least 3 days at 4ºC.  The support is then washed several times with 0.10 M 
phosphate buffer, pH 8.0, and suspended in 2-3 mL of this pH 8.0 buffer and combined with 2.5 
mg sodium borohydride, which is added in three equal portions over 90 min while the mixture is 
allowed to react at room temperature in a fume hood.  The final support is washed with 0.5 M 
sodium chloride in 0.10 M potassium phosphate buffer, pH 8.0, followed by further washing 
with 0.067 M potassium phosphate buffer, pH 7.4.  The support can be stored in the 0.067 M 
phosphate buffer, pH 7.4, and at 4ºC until use.  A control support can be prepared in the same 
manner, but with no protein being added during the immobilization step [47-52]. 
 Several methods have also been applied for immobilizing AGP onto HPLC-grade porous 
silica [64-66].  The AGP support that was used in this particular study was prepared using 
hydrazide-activated silica and mildly-oxidized AGP; this procedure has been shown to produce 
immobilized AGP with drug binding properties that mimic those for soluble AGP [65,66].  This 
hydrazide method is illustrated in Figure 2(b).  In this immobilization scheme, silica is first 
converted into or obtained in a diol-bonded form and oxidized with periodate to give an 
aldehyde-activated form [65].  The aldehyde-activated silica is then reacted with an excess of 
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oxalic dihydrazide to give hydrazide-activated support [65], with remaining aldehyde groups on 
the support later being reduced by adding sodium borohydride.  The hydrazide-activated support 
is then combined with AGP that has undergone mild oxidation to produce aldehyde groups in its 
carbohydrate chains, which can form a stable hydrazone bond with the support. 
The following conditions can be used to immobilize AGP to Nucleosil Si-300-7 silica by 
the hydrazide method [65].  To make 0.10 g of AGP silica, 0.10 g of diol silica is first oxidized 
to form aldehyde groups by placing this support into 2 mL of 90% acetic acid that contains 0.10 
g periodic acid.  This mixture is covered with aluminum foil and shaken for 2 h at room 
temperature.  The aldehyde-activated silica is then washed several times with water.   The 
aldehyde-activated silica is placed into 17.5 mL of a 0.10 M phosphate solution, pH 5.0, and 
allowed to react for 2 h at room temperature with a five-fold mole excess of oxalic dihydrazide 
versus the initial diol groups on the support (i.e., 1 mg/mL oxalic dihydrazide, in this case).  The 
support is then washed several times with 0.10 M phosphate buffer, pH 7.0.  Any remaining 
aldehyde groups on the support are reduced by adding 20 mL of 0.10 M potassium phosphate 
buffer, pH 8.0, that contains a 25-fold mole excess of sodium borohydride versus the initial diol 
groups, with this mixture being allowed to react for 90 min at room temperature in a fume hood.  
The final support is washed with 0.10 M phosphate buffer, pH 7.0, before its use in the 
immobilization of AGP [65].   
To make 0.10 g of AGP silica, 10 mg of AGP is next dissolved in 2 mL of a 0.020 M 
sodium acetate solution, pH 7.0, that also contains 0.15 M sodium chloride, according to the 
literature for use in the mild oxidation of AGP [66].  This solution is combined in a 1:1 (v/v) 
ratio with a solution that contains 20 mM periodic acid in the same buffer.  This mixture is 
covered in aluminum foil and allowed to react for 10 min in the dark at room temperature, with 
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the reaction then being quenched by adding 0.25 mL of ethylene glycol per milliliter of solution.  
These conditions result in approximately five aldehyde groups being generated per AGP [66].  
The oxidized AGP can be purified by washing it with 0.10 M phosphate buffer, pH 7.0, in 
centrifugal filtration devices [64], with the final volume of the AGP solution then being adjusted 
to 2.0 mL with the same buffer.  This solution of oxidized and purified AGP is mixed with 0.10 g 
of hydrazide-activated silica, placed on an inversion shaker, and allowed to react for one week at 
4ºC.  The reaction is stopped by centrifuging the slurry, removing the supernatant, and washing 
the support with 0.10 M phosphate buffer, pH 7.0.  Any unreacted hydrazide groups that remain 
on the support can be capped by adding a ~50-fold mol excess of glyceraldehyde versus the 
support’s original hydrazide content, with this mixture being shaken for 6 h at 4ºC.  The final 
support is washed with 0.10 M phosphate buffer, pH 7.0, and stored in the same buffer at 4ºC 
until further use [53,54].  A control support can be prepared in a similar manner but with no AGP 
being added to the hydrazide-activated silica during the immobilization step.   
In the examples that are cited in this report, microcolumns and columns with various 
sizes (i.e., lengths of 1-50 mm and 2.1 mm i.d.) were used with the immobilized HSA and AGP 
supports and control supports.  For columns that had lengths of 5 mm or longer, the supports 
were downward slurry packed into stainless steel columns.  The packing pressure was usually 
4,000 psi (or 28 MPa) for this type of column.  For microcolumns that had lengths below 5 mm, 
the supports were packed in a similar manner but instead used a frit-in-column design [67].  The 
typical packing pressure for these shorter columns was 3,000 psi (20 MPa).  Either set of packing 
conditions used a neutral buffer such as 0.067 M phosphate buffer, pH 7.4, as the packing 
solution, with the columns being stored at 4 °C in the same buffer when not in use. 
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2.3. Apparatus 
Most standard HPLC systems can be adapted for use in ultrafast affinity extraction.  For 
the examples given in this report, a single-column chromatographic system for ultrafast affinity 
extraction usually consisted of such components as a PU-2080 plus pump from Jasco (Easton, 
MD, USA), a six-port LabPro valve from Rheodyne (Cotati, CA, USA), a Jasco UV-2075 UV 
absorbance detector, a Jasco AS-2057 plus autosampler, and a Jasco CO-2067 plus column oven.  
However, other types of pumps, detectors, autoinjectors and equipment for column temperature 
control can also be employed for this type of system.  The general design for this single-column 
system is shown in Figure 3(a).  During the binding experiments that were carried out for the 
examples cited in this report, the temperature of the column oven was often maintained at 37 ºC, 
although other temperature can also be utilized.  The size used for the microcolumn in this 
system will depend on the affinity of the injected drug/solute for the immobilized binding agent 
and the flow rates that are to be used for isolation of the free drug/solute fraction [47,49-52].  
However, microcolumn sizes in the range of 1-10 mm long and 2.1 mm I.D. have been used in 
prior work with this approach, with this size tending to increase as the affinity of the injected 
drug or solute decreases for the immobilized binding agent [48-53].  
As is shown in going from Figure 3(a) to 3(b), the basic set up of a two-column system 
for ultrafast affinity extraction and the equipment used in this system are similar to those for the 
single-column system.  The main additions are a second column, which is usually larger than the 
first, and a six-port valve, which is used to place the second affinity column in line with the first 
column.  After elution of the non-retained peak from the first column, the position of the six-port 
valve is switched to carry a portion of the retained peak from the first column and onto the 
second affinity column.  The components eluting from the second column are then monitored by 
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a device such as an absorbance detector.  This two-column approach can be used to provide a 
higher level of resolution between the retained and non-retained drug fractions than can be 
obtained when using only a single-column system [53].  Typical sizes for the second column in 
this system have been 5-25 mm long and 2.1 mm I.D., with the column size that is needed again 
tending to increase as the affinity of the drug/solute decreases for the immobilized binding agent 
[48,50,52,53].  
3.      Methods 
3.1.    Optimization of ultrafast affinity extraction 
The general scheme for the use of a single-column affinity system to measure free drug 
fractions is shown in Figure 4(a) [54].  First, the drug and protein mixture is allowed to incubate 
at the desired temperature prior to injection of this mixture onto an affinity microcolumn that 
contains an immobilized binding agent for the drug (e.g., immobilized HSA or AGP).  At low-to-
moderate flow rates, some of the protein-bound drug in the sample will dissociate as the sample 
passes through the microcolumn, as represented by the top portion of Figure 4(a).  This 
dissociated drug increases the measured free drug fraction and provides data that can be used to 
estimate the dissociation rate constant for the soluble drug-protein complex [54].  As the sample 
passes through the microcolumn at a sufficiently high flow rate, only the original free fraction of 
the drug is retained by the microcolumn as the soluble, bound form of the drug and excess 
soluble protein are eluted as a non-retained peak.  As is shown in the bottom portion of Figure 
4(a), the free drug fraction that is measured under these conditions can be used to estimate the 
actual or apparent equilibrium constant for the drug-protein interaction in solution.   
Figure 4(a) shows how the residence time for a sample inside an affinity microcolumn 
can play an important role when using ultrafast affinity extraction to measure free drug fractions 
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[47,49,51-54].  This factor can be modulated by altering either the column size or flow rate 
[47,49-52].  The effect of changing the flow rate during ultrafast affinity extraction is shown in 
Figure 5.  In this illustration, the apparent free fraction for a drug decreases as the flow rate is 
increased from a low-to-moderate level and reaches a constant value at higher flow rate [54].  At 
the low-to-moderate flow rates (i.e., less than 0.85 mL/min, in this example), some drug that was 
bound to proteins in the sample is able to dissociate from these proteins, resulting in an increase 
in the apparent free drug fraction.  However, this apparent free drug fraction approaches the true 
value when the flow rate becomes high enough to keep this dissociation at a negligible level.  
The flow rate that is needed to obtain this condition will vary from one drug and protein system 
to the next, but generally occurs when the sample residence time is on the order of a few hundred 
milliseconds [47,49,51,53].   
Figure 4(b) shows the general scheme for using ultrafast affinity extraction with a two-
column system to measure free drug fractions [53].  In this case, an affinity microcolumn and 
longer affinity column can be connected in series during part of the separation.  The drug and 
protein mixture is first injected onto only the affinity microcolumn, which will extract and retain 
the free drug fraction from the sample while the bound form of the drug and excess soluble 
protein elute as non-retained components [50,52,53].  For samples that are complex or that 
contain a large amount of protein, baseline resolution may not always be obtained between the 
retained and non-retained peaks of the first column.  In this situation, a second and longer 
affinity column can be placed online with the affinity microcolumn after most of the non-
retained components have eluted.  A part of the free drug fraction that is retained by the first 
column is then delivered to the second column to enable further separation of the free drug 
fraction from other sample components [50,52,53]. 
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One important factor to consider during this transfer process is the time that is used to 
switch the second column online with the first [50,52,53].  The effect of varying this time on the 
measured free drug fraction is illustrated in Figure 6 [53].  When the switching time is short, the 
result is in an increase in the apparent free drug fraction due to contamination from non-retained 
components in the sample, as shown in Figure 6(b).  When the switching time is made longer, 
this contamination is minimized and a consistent free drug fraction is observed.  However, using 
switching times that are too long will also create a loss in precision for the measured free drug 
fraction as less of the retained peak enters the second column, as demonstrated in both Figures 
6(a) and 6(b).  As a result, use of an intermediate switching time is generally recommended to 
provide both good accuracy and reasonable precision for the measured free drug fraction [53]. 
 
3.2. Measurement of free drug fractions 
The first way ultrafast affinity extraction can be used is to measure the free fraction of a 
drug in a drug/protein mixture or more a complex sample that contains the drug and binding 
agents [47].  Figure 7 shows some typical chromatograms from such a study, as obtained with an 
HSA microcolumn and by using samples that contained the drug tolbutamide or a mixture of 
tolbutamide and soluble HSA [50].  Once this type of separation has been optimized (i.e., as 
described in the previous section for work at column residence times that minimize drug-protein 
dissociation in the sample), the free drug fraction in the sample can be determined by dividing 
the retained peak area observed for the drug by the total peak area that is measured for a standard 
that contains the same total concentration of the drug but no protein [50,52,53].  It has been 
demonstrated in several studies that good agreement is seen in the free fractions that are 
measured under these conditions when compared to the results that are obtained by a reference 
method such as ultrafiltration [45-48,52,53].  This method has also been employed in examining 
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systems that span a wide range of affinities (see Section 3.4), free fractions and free solute 
concentrations.  This has included free drug and hormone fractions that have ranged from 0.09% 
to 92% [44,47,48,50,52], with precisions that are often comparable to or better than those 
obtained by reference methods [44-48,53].         
 
3.3. Determination of rate constants 
Another way ultrafast affinity extraction can be employed is to determine the dissociation 
rate constant (kd) for a drug-protein complex.  This can be accomplished by measuring the free 
drug fraction at low-to-medium flow rates when a drug-protein mixture is injected onto the 
affinity microcolumn [49].  The apparent free fractions are then measured, as described in the 
previous section, and used to prepare a plot according to Eqs. (1) or (2) [49].  
              
       
       
                                    (1) 
                              
 
       
                                            (2) 
In these two equivalent equations, F0 is the true original free fraction of drug D in the sample 
(e.g., as determined at high flow rates), and Ft is the apparent free fraction that is measured at 
low-to-moderate flow rates (i.e., conditions where the drug-protein complex DP is allowed to 
dissociate for time t in the microcolumn).  According to Eqs. (1) and (2), plots made of either 
ln[(1 – F0)/(1 - Ft)] or ln[1/(1 - Ft)] versus t should result in a linear relationship in which the 
slope provides the dissociation rate constant kd for the complex of the drug with the soluble 
protein [49]. 
Eq. (1) can be used when a direct and separate measurement can be made of F0, as 
discussed in Section 3.2.  As an alternative, Eq. (2) allows the value of F0 to instead be obtained 
from the intercept of a plot of ln[1/(1 - Ft)] versus t.  This second approach tends to provide a 
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less precise estimate of F0 than when using a direct measurement of this parameter.  However, 
this second method can also be more useful for obtaining both F0 and kd in situations where 
sufficiently high flow rates cannot be used with an affinity microcolumn to directly measure F0 
[49].    
Figure 8 shows some plots that are acquired when using Eqs. (1) and (2) for kinetic 
studies, as based on data for the drug verapamil and soluble AGP [54].  Table 1 lists some 
dissociation rate constants that have been obtained when using ultrafast affinity extraction with 
either Eq. (1) or (2) to examine various drugs in the presence of soluble HSA or AGP [49,54].  
The dissociation rate constants that have been measured by this method have ranged from 10
-2
 to 
10
1
 s
-1
, as have been obtained with systems with binding affinities spanning from 10
4
 to 10
9
 M
-1
 
and with good agreement with literature values [12,49,51,52,70].  In the case of a binding agent 
such as HSA that tends to have simple saturable interactions with drugs [49], consistent values 
for dissociation rate constants have been acquired with this method when varying either the drug 
or protein concentration that is used in the sample [49,51].  However, more complex binding 
agents such as AGP have been found to have concentration-dependent values for their apparent 
dissociation rate constants [54].  This latter effect has been proposed to be the result of a 
combination of dissociation mechanisms that may be present in this type of drug/protein system 
[54,68,69]. 
    
3.4. Determination of binding constants 
Use of a small column residence time can result in free drug fractions that can be 
employed to estimate the equilibrium constant for a drug-protein interaction (e.g., as related to 
the original free drug fraction in the initial sample).  For instance, a free fraction that is 
determined under these conditions can be used with Eq. (3) to provide the association 
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equilibrium constant (Ka) for a drug-protein system that has a single-site, saturable interaction 
[47].  
                                   
          
                        
                                     (3) 
In this equation, [A]0 and [P]0 are the total concentrations of the drug/analyte and soluble protein 
in the injected sample, and F0 is the original free fraction of the drug/analyte in the sample at 
equilibrium (i.e., as measured at a flow rate that minimizes drug-protein dissociation in the 
column).  The same general relationship can be used to estimate the global affinity constant 
(nKa’) for a system in which there are multiple, independent and saturable interactions between a 
drug and protein [47].  Although weaker, non-specific interactions may also make up part of 
estimates for this global affinity constant, their contribution in most cases should be small when 
compared to the contributions by higher affinity sites in the system.  This last feature is reflected 
by the good agreement that has been seen in several past studies between the global affinities that 
are measured by this approach and those that have been obtained by other methods, as has been 
noted for systems with affinities that have spanned from 10
3
 – 109 M-1 [47-53].    
Another method that can be used to estimate the equilibrium constants for drugs with 
soluble proteins is based on the estimate of F0 that is obtained in kinetic studies when using Eq. 
(2) [49].  In this approach, the value of F0 can be acquired from the intercept of a plot of ln[1/(1 - 
Ft)] versus t, which can then be used along with Eq. (3) to find Ka or nKa’. Table 2 lists some 
association equilibrium constants and global affinities that have been obtained in prior work 
when using either of these methods for various drugs and soluble forms of HSA or AGP [49,54].  
A more complex model, as described by Eqs. (4-6), can be used with ultrafast affinity 
extraction and free fraction measurements to examine the interaction for a drug with two separate 
binding agents.  This type of model has been used to measure the association equilibrium 
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constants or global affinities for a number of drugs in serum which can bind to both AGP and 
HSA [53]. 
    
       
                      
                        (4) 
where,                                                   (5) 
                     
            
          
                         (6) 
In these equations Ka,A is the apparent or global affinity constant for a drug/analyte with AGP; 
[D-A]eq is the equilibrium concentration for this drug’s complex with AGP; F is the measured 
free drug fraction; [D]0, [A]0 and [H]0 are the original total sample concentrations of the drug, 
AGP and HSA, respectively; [D-H]eq is the concentration of the drug’s complex with HSA; and 
Ka,H is the association equilibrium constant or global affinity constant of drug with HSA [53].   
Another model that has been used with free fraction analysis is a mixed-model, as 
described by combining Eq. (3) and Eqs. (7-8).  This particular model combines a non-saturable 
process, as represented by Eq. (7), with saturable binding, as shown in Eq. (3), for systems that 
may have both types of interactions present [54]. 
   
    
   
                                             (7) 
                                                            
          
         
                       (8) 
In these equations, [D] is the solution-phase concentration of the drug; [DP] is the concentration 
of the same drug that has partitioned into the protein; KD is the distribution constant; CD is the 
total concentration of the drug; Ka is the association equilibrium constant; and [P0] is again the 
total concentration of the soluble protein [54].  
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In general, a single-column system is usually sufficient to acquire an equilibrium constant 
for a drug-protein system when the drug and protein are present at similar concentrations (e.g., if 
the concentration of the protein is one- to two-times the drug’s concentration) [47,49,54].  A 
two-column system is more commonly employed with complex samples or when there is a large 
difference in the concentrations of the drug and protein [48,50,52,53].  Complex mixtures that 
have been examined with two-column systems have included samples that contain more than one 
form of a drug (e.g.,  drug enantiomers) [48], drug/protein mixtures that are prepared at 
therapeutic or physiological concentrations, and drugs that are present in clinical samples [50-
52].  
Ultrafast affinity extraction has been used in equilibrium studies for systems that have 
varied from weak-to-strong binding [71].  For instance, this method has been used with affinity 
columns containing antibodies to measure the free fraction of warfarin in samples containing a 
mixture of this drug and HSA [43].  Ultrafast affinity extraction has also been utilized in 
combination with flow-based displacement immunoassays to measure the free fractions of 
thyroxine and phenytoin in clinical samples [44-46].  In addition, this method has been used to 
measure the free fractions and equilibrium constants for various drugs with HSA/glycated HSA 
[47,49,50,52] or AGP [53,54] and to study the interactions of testosterone with both HSA and 
sex-hormone binding globulin [51]. 
4. Conclusion 
This report has described the method of ultrafast affinity extraction and has shown how 
this approach can be employed as a tool for studying drug- or solute-protein interactions.  The 
general principles of this method were discussed, along with various experimental factors to 
consider in the design and optimization of this technique and methods for analyzing the resulting 
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data for equilibrium or kinetic studies.  Several applications for this approach were also 
described.  These applications included measurement of the free fractions for drugs and other 
solutes in simple solutions or biological samples [43-54], and the use of this method to 
characterize the equilibrium constants or rate constants for drug/solute-protein interactions [43-
54].  These applications and experimental considerations were illustrated by using data that have 
been obtained through this method for various drugs and solutes that are known to bind to HSA 
and AGP and with binding strengths that have ranged from 10
3
 to 10
9
 M
-1
 [44-46,52,53].   
Several advantages for ultrafast affinity extraction have been noted in these applications. 
For instance, this is a label-free method that can be used with a variety of detection techniques 
[12]. Unlike other common approaches for biointeraction analysis (e.g., traditional HPAC and 
surface plasmon resonance), this method allows for solute-protein binding to be examined 
directly in solution, rather than between a solute and immobilized binding agent [12,49,51].  
Other appealing features of this method include its ability to work with either low or high affinity 
systems, its need for only a small amount of sample, and its ability to provide results in few 
minutes after sample injection [12,52].  One current limitation of this method is that some 
preliminary studies must be conducted to determine the correct column sizes and flow rates to 
employed to extract the free solute fraction and separate it from non-retained sample components 
[12,49,70].  However, this limitation is being overcome as more information and experience is 
being obtained with this technique and further applications are being reported for this approach 
[47-53].  This additional information and set of applications should, in turn, allow for even more 
uses for this method in the future in areas that include biochemical or pharmaceutical research 
and clinical analysis [12,44-53].      
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5. Notes 
5.1. The diol coverage of the modified Nucleosil Si-300 support that was used for the 
examples cited in this report was around 300 µmol diol/g silica.  This value may differ 
when using other types of silica and will depend on the pore size and surface area of the 
support [72,73].  
5.2. The degree of capture for a drug in ultrafast affinity extraction will vary with the flow 
rate, amount of immobilized binding agent, and size of the affinity microcolumn.  The 
examples cited in this report typically had a capture efficiency of 95% or more when 
using HSA and AGP microcolumns [47,49]. 
5.3.  When ultrafast affinity extraction is used with serum, these samples should be filtered 
(e.g., twice using syringe filters with 0.2 µm nylon membranes) prior to their 
combination with a drug or injection onto an HPLC system [52,53]. 
5.4. Although some immobilization schemes can lead to non-specific interactions of a solute 
to a support, it has been noted that this does not lead to any major effects in the 
measurement of binding constants by ultrafast affinity extraction [53].  This is the case 
because the affinity microcolumn is used only to capture and measure the free solute 
fraction.  The actual binding event that is examined is the solution-phase interaction of 
the drug/solute with a soluble protein, and this process is not altered by non-specific 
interactions due to the support [53]. 
5.5. The protein content of the supports that were used here to illustrate the applications of 
ultrafast affinity extraction were 22 mg AGP/g silica and 46-66 mg HSA/g silica [47-53].  
The use of supports with smaller or larger protein contents may require the use of column 
sizes that are slightly larger or smaller, respectively, than those used in these particular 
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examples, as the protein content will affect the degree of retention and separation that is 
obtained for the retained free drug fraction versus non-retained sample components [47]. 
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Figure legends 
Figure 1.  The general basis for ultrafast affinity extraction. 
  
Figure 2.  (a) The Schiff base method for the immobilization of HSA and (b) the hydrazide 
method for the immobilization of AGP. 
 
Figure 3.  The typical designs for systems used in ultrafast affinity extraction based on (a) a 
single-column or (b) a two-column system. 
 
Figure 4.  General approaches for the separation and analysis of free drug or solutes fractions by 
using ultrafast affinity extraction using (a) a single-column system or (b) a two-
column system.   
 
Figure 5.   Effect of injection flow rate on the column residence time (dashed line) and apparent 
free drug fractions (solid line), as illustrated for 10 µL injections of samples 
containing 1 µM propranolol and 20 µM soluble AGP onto a 2 mm × 2.1 mm i.d. 
AGP microcolumn at pH 7.4 and 37 ºC.  Reproduced with permission from Ref. [54].   
 
Figure 6.   Effect of changing the valve switching time in ultrafast affinity extraction when using 
a two-column system.  These effects are illustrated for (a) the recovery of 
carbamazepine at 0.5 mL/min on a 10 mm × 2.1 mm i.d. AGP column that was 
placed on-line with a 5 mm × 2.1 mm i.d. AGP column at various times following the 
injection of a 3 µL sample mixture of 15 µM carbamazepine/20 µM AGP/481 µM 
HSA onto the first column at 3.0 mL/min, and (b) the apparent free drug fractions that 
were measured by using the same chromatographic conditions and sample when 
using a two-column system.  All of the times show represent the elapsed interval after 
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sample injection.  The error bars represent ± 1 standard error of the mean (n = 3) and 
all the measurements were made at pH 7.4 and 37 ºC.  Reproduced with permission 
from Ref. [53].   
 
Figure 7.  Typical chromatograms obtained from the application of 185 μM tolbutamide 
(therapeutic concentration) in the absence or presence of 526 μM HSA (physiological 
concentration) onto a single 5 mm × 2.1 mm i.d. HSA microcolumn at 2.25 mL/min.  
Reproduced with permission from Ref. [50].   
 
Figure 8.  Analysis of the interactions by verapamil with soluble AGP by using ultrafast affinity 
extraction and Eqs. (1) and (2).  The samples contained 10 µM verapamil and 20 µM 
AGP.  The error bars represent a range of ± 1 S.D.  These results are based on data 
from Ref. [54]. 
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Figure 1
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Figure 2
(a) Schiff base method
(b) Hydrazide method
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Figure 3
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Figure 7
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Table 1.   Dissociation rate constants measured for various drugs with soluble HSA and 
soluble AGP by using ultrafast affinity extraction on HSA and AGP 
microcolumns
a 
                           Dissociation rate constant, kd (s
-1
)   
Drug and HSA Estimate, Eq. (1)
b
 Estimate, Eq. (2) Literature [Ref.]  
Warfarin 0.80 (± 0.05) 0.72 (± 0.05) 0.41-2 [74-76] 
Tolbutamide 0.59 (± 0.03) 0.58 (± 0.04) 0.49 (± 0.15) [75] 
Acetohexamide 0.67 (± 0.03) 0.63 (± 0.03) 0.58 (± 0.02) [75] 
Verapamil 0.35 (± 0.02) 0.36 (± 0.02) 0.38 (± 0.05) [77] 
Gliclazide 0.61 (± 0.02) 0.59 (± 0.04) Not reported  
Chlorpromazine 3.96 (± 0.13) 3.35 (± 0.30) Not reported  
 
Drug and AGP 
(drug:protein 
concentrations) 
 
Estimate, Eq. (1)
b
 
 
Estimate, Eq. (2) 
 
Literature [Ref.] 
Verapamil (10 µM:20 
µM) 
0.62 (± 0.05) 0.59 (± 0.07) Not reported 
Lidocaine (15 µM:20 µM) 0.63 (± 0.05) 0.61 (± 0.05) 0.73 (± 0.07) [77] 
Imipramine (3 µM:40 
µM) 
0.27 (± 0.04) 0.24 (± 0.04) 0.13 (± 0.01) [54] 
Disopyramide (3 µM:25 0.29 (± 0.04) 0.28 (± 0.06) 0.38 (± 0.02) [54] 
  
45 
 
µM) 
Chlorpromazine (3 µM:40 
µM) 
0.60 (± 0.03) 0.56 (± 0.02) 0.10 (± 0.01) [54] 
Propranolol (1 µM:20 
µM) 
0.24 (± 0.02) 0.24 (± 0.02) S-Propranolol 
0.19 (± 0.01) [54] 
 
a
The values listed in this table are from Refs. [49,54].  All of the kd values obtained by ultrafast 
affinity extraction were measured at pH 7.4 and 37 
o
C.  The samples used in the binding studies 
with HSA that contained 10 μM of a given drug and 20 μM HSA.  In the work with AGP, the 
drug and protein concentrations are given in the table. The values in the parentheses represent a 
range of ± 1 S.D., as determined from the slopes of the best-fit lines constructed according to 
Eqs. (1) and (2). 
b
These values were found by using Eq. (1) when a point at the origin was included in the data 
set. 
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Table 2. Equilibrium constants measured for various drugs with soluble HSA and AGP by 
using ultrafast affinity extraction on HSA and AGP microcolumns
a
 
                                                 Association equilibrium constant, Ka,  
                                                 or global affinity constant, nKa’ (M
-1
) 
Drug and HSA Estimate, Eq. (3) Estimate, Eqs. (2-3)  Literature [Ref.] 
Warfarin 2.4 (± 0.4) × 10
5
 1.6 (± 0.2) × 10
5
 2.0-5.7 × 10
5
 [78-80] 
Tolbutamide 1.1 (± 0.4) × 10
5
 0.9 (± 0.2) × 10
5
 1.1 (± 0.1)  × 10
5 
[81]
b
 
Acetohexamide 1.8 (± 0.5)  × 10
5
 1.3 (± 0.1)  × 10
5
 1.7( ± 0.1)  × 10
5 
[82]
b
 
Verapamil 1.5 (± 0.4) × 10
4
 1.6 (± 0.2) × 10
4
  1.4 ( ± 0.1)  × 10
4 
[83]
c
 
Gliclazide 8.0 (± 0.6)  × 10
4
 6.9 (± 1.0)  × 10
4
 7.9 (± 0.1) × 10
4 
[84]
b
 
Chlorpromazine 6.2 (± 0.5)  × 10
4
 4.9 (± 0.5)  × 10
4
 6.4 × 10
4
 [85] 
    
 
  
47 
 
Drug and AGP 
(drug:protein 
concentrations) 
Estimate, Eq. (3)  
Estimate, Eqs. (2-3) 
Literature [Ref.] 
Verapamil (10 µM:20 
µM) 
1.2 (± 0.1) × 10
5
 1.0 (± 0.2) × 10
5
 1.2 × 10
5
 [86,87] 
Lidocaine (10 µM:20 µM) 1.1 (± 0.2) × 10
5
 1.6 (± 0.4) × 10
5
 1.1 – 1.7 (± 0.2) × 105 
[88] 
Imipramine (10 µM:20 
µM) 
1.5 (± 0.1) × 10
5
 1.6 (± 0.4) × 10
5
 1.4 – 1.7 × 105 [89,90] 
Disopyramide (5 µM:7.5 
µM) 
6.9 (± 0.3) × 10
5
 6.7 (± 1.1) × 10
5
 6.3 × 10
5
 [91] 
Chlorpromazine (5 µM:10 
µM) 
5.4 (± 0.4) × 10
5
 3.9 (± 0.8) × 10
5
 4-17 × 10
5
 [92,93] 
Propranolol (5 µM:10 
µM) 
2.9 (± 0.2) × 10
5
 3.6 (± 0.8) × 10
5
 3-14 × 10
5
 [68,94] 
 
a
The values listed in this table are from Refs. [49,54].  Other conditions were the same as in 
Table 1.  The values in parentheses represent a range of ± 1 S.D., as determined by error 
propagation. 
b
The global affinity constants for these drugs were calculated from data in the given references.
  
c
This value represents the average association equilibrium constant for R- and S-verapamil at 
their high affinity site on HSA. 
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Highlights 
 Ultrafast affinity extraction is discussed as a method for studying drug-protein binding. 
 Various practical aspects are considered in the design and use of this approach. 
 This method is illustrated using data obtained various drugs with serum proteins. 
 Applications that are described include both kinetic and equilibrium studies.     
 
 
 
